2020 was supposed to be a year of immense market growth, but so far whenever a major North American index rallied to a 
record high, it seemed to be cut short by a different major story sweeping headlines - the outbreak of the novel COVID-19 coronavirus.
Investors have been concerned about the virus’ impact on markets and even major pharmaceutical companies were struggling to come up with a successful treatment, simply because they didn’t know much about it.
Vancouver, BC-based Roadman Investments Corp. (TSX-V: LITT, OTC: RMANF, Forum) has just found a company that is focused on conducting further R&D for the purposes of preventing the spread of coronavirus and other similar potentially pathogenic respiratory viruses such as influenza, para-influenza, and syncytial viruses.
LITT announced on February 14th, 2020 that it had acquired CLOV Biopharma Corp., a company that is working in partnership with Dr. James Hudson, one of Canada’s foremost virologists, in further studying and developing mechanisms aimed at stopping the spread of pathogenic respiratory viruses, such as the deadly COVID-19 coronavirus, utilizing cedar leaf (Thuja plicata) oil vapour (or CLOV).
Roadman, a Canadian venture capital & advisory firm, signed the letter of intent to acquire all of CLOV Biopharma’s shares earlier last week and it intends to use its exclusive license to manufacture, or source, a diffuser that is functional with cedar oil that may be effective in killing viruses to prevent them from spreading. CBP’s exclusive license also includes certain know-how, industry knowledge and experience for the pharmaceutical, healthcare, and biotechnology industries.
Roadman Investments’ CEO Luke Montaine commented for investors that CBP’s management and advisors bring significant expertise along with over 10 years’ experience in utilizing cedar leaf oil vapour in a variety of both clinical laboratory and real world commercial scenarios in studying and combatting the spread of numerous viruses and toxic mold.
“We have the privilege to be working closely with Dr. James Hudson, a leading virologist and professor emeritus from the University of British Columbia, to further study and potentially bring products to market that may help combat an array of viruses. It is highly encouraging that Dr. Hudson’s findings show that CLOV appears to have selective toxicity that targets viruses but does not do any harm to healthy human epithelial cells.”
(Video via UQ Faculty of Medicine.)
Dr. Hudson is a professor emeritus from the University of British Columbia and is widely considered to be one of the foremost virologists in Canada. His previous studies have shown that most human respiratory viruses that have been tested are vulnerable to cedar leaf oil and cedar leaf oil vapour. The hypothesis is that COVID-19 could also be vulnerable.
Beyond COVID-19, Dr. Hudson’s previously published manuscripts have concluded that CLOV killed several other human respiratory viruses, including Influenza, Rhinovirus, Adenovirus, as well as the Herpes simplex virus. Further tests also found that CLOV isn’t cytotoxic (meaning it isn’t toxic to living cells) and it also partly reversed the pro-inflammatory effect caused by Rhinovirus infection - it acts as a multifunctional therapeutic agent.
Since the beginning of the year, the COVID-19 coronavirus had been causing a drag on major markets in some form or another. Potential treatments are definitely much needed as the virus has killed more than 1,350 people in China alone, while it disrupted the second largest economy in the world and 65,000 cases have been reported globally, so far.
As scientists and corporations race to find a possible treatment, the work being done between Roadman Investments Corp. and CLOV Biopharma Corp. could potentially be a game-changer that investors should keep an eye on for further developments.
roadmancorp.com
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.